Product Reports Resources Pricing Login Book a demo

Biofourmis

Biotech & Life Sciences · Boston, United States · Founded 2015

Biotechnology company that augments personalized care and therapies using digital therapeutics

Valuation $1–2.5B
Headcount 100–500
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Biofourmis and the history behind them.
Power Law Unicorn$1–10B valuation tier
Knowledge graph
Market map Digital therapeutics

Talent graph

Biofourmis's talent

Book a demo to see the people
Employees mapped 109 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

14 investors on Biofourmis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Eden Strategy Institute
SpesNet Pte.
Series A 2 investors entered at this stage
Openspace Ventures
Aviva Ventures
Series B+ 10 investors entered at this stage
Sequoia
CVS Health
Jinke Entertainment Culture
General Atlantic
SoftBank Vision Fund
MassMutual Ventures
EDBI
Intel Capital
SoftBank
SGInnovate

Global footprint

Where Biofourmis has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States47.3%
🇮🇳 India45.1%
🇸🇬 Singapore6.6%
🇨🇦 Canada0.7%
🇬🇧 United Kingdom0.5%
Top 5 of 6 shown
Web traffic by country
7K monthly visits
across markets
🇲🇾 Malaysia54.3%
🇺🇸 United States32.9%
🇮🇳 India11.4%
🇩🇪 Germany1.4%
Top 4 markets shown

Capital deployed

Biofourmis's 3 investments and acquisitions.

Every disclosed deal where Biofourmis appeared as a backer or acquirer, 2019–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Biofourmis's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Biofourmis's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Biofourmis

        An AI-synthesized read of the highest-engagement posts about Biofourmis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Biofourmis on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles